We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.06 | 0.05% | 127.57 | 127.73 | 126.76 | 127.32 | 6,551,460 | 22:03:47 |
From May 2019 to May 2024
By Inti Landauro
PARIS--French pharmaceutical giant Sanofi SA (SAN.FR) Monday said it filed a lawsuit against Merck & Co.'s international unit for alleged patent infringements.
In the filing in the U.S. district court of Delaware, Sanofi said it claims that Merck Sharp & Dohme Corp. violated as many as 10 patents held by the French company, including ones for its blockbuster diabetes treatment Lantus and its insulin delivery device soloSTAR.
Sanofi said it started the legal proceedings against Merck following the U.S. company's filing for new drugs applications with the U.S. Food & Drug Administration.
Paris-based Sanofi is one of the world's biggest makers of diabetes drugs, though that part of the business is under pressure from increasingly cost-conscious heath-care systems. The company expects revenue from diabetes drugs to decline over the coming years as competition between insulin makers intensifies.
-Write to Inti Landauro at inti.landauro@wsj.com
(END) Dow Jones Newswires
September 19, 2016 01:53 ET (05:53 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
